固态肿瘤检测全球市场报告：趋势、预测和竞争分析（至 2031 年）

全球固态肿瘤检测市场前景光明，医院、製药和生物技术公司、受託研究机构和学术研究机构都存在机会。预计到 2031 年，全球固态肿瘤检测市场规模将达到 16,992 亿美元，2025 年至 2031 年的复合年增长率为 3.5%。市场的主要驱动力是补充剂和类固醇的使用增加，以及吸烟和饮酒等不健康习惯的增加。

• Lucintel 表示，根据应用情况，由于全球皮肤肿瘤和相关疾病的发生率不断增加，预计黑色素瘤将在预测期内出现最高增长。
• 根据最终用途，由于肿瘤和慢性病的盛行率上升，预计医院将呈现最高的成长。
• 根据地区划分，预计北美将在预测期内出现最高增长，这得益于强大的医疗保健基础设施支持下各种器官特异性癌症病例的增加。

固态肿瘤检测市场的策略性成长机会

固态肿瘤检测领域的几何发展涵盖了与组成地理系统的基础区域相关的各种策略排除选项。具体潜在价值的发展将有助于解决改善诊断过程和治疗结果的挑战。

• 引入个人化医疗：个人化医疗可以设计适合每位患者的独特测试。透过全面研究基因，可以设计出更有效地治疗疾病和改善患者健康状况的新策略。
• 液态切片市场演变：看到非侵入性检测的趋势日益增长，公司看到了增强液态切片系统和服务的机会。这种趋势不仅提高了患者的舒适度，还能更好地衡量治疗效果。
• 将AI技术应用于诊断：AI在固态肿瘤检测中的应用为智慧诊断解决方案的开发开闢了新的途径。这些可以系统地筛选大量信息，以提高测试准确性，提高工作流程效率并缩短诊断时间。
• 早期检测的需求日益增加：随着我们对癌症及其早期症状的了解不断加深，对更好的筛检工具的需求也日益增加。因此，致力于向市场提供更好的早期检测测试的主要企业将能够更好地从行业日益增长的需求中获益，进而从不断扩大的客户群中夺取更大的市场占有率。
• 瞄准已开发市场－发展海外业务：新兴市场，尤其是亚洲和非洲的市场，可望成为固态肿瘤检测业务的绝佳途径。能够策略性地进入这些地区的公司会发现，越来越多的患者正在寻求更好的诊断方法。

这些前瞻性的成长策略正在重新定义固态肿瘤检测市场，并专注于精准医疗、技术和新型诊断解决方案。抓住这些机会的供应商可能会获得更多的市场占有率并提高为患者提供的护理品质。

固态肿瘤检测市场驱动因素与挑战

与目前的固态肿瘤检测市场类似，未来的固态肿瘤检测市场也受到多种技术、经济和监管因素的困扰，这些因素既是驱动因素，也是限制因素。随着环境的不断变化，相关人员了解这些动态非常重要。

固态肿瘤检测市场受以下因素驱动：

1. 技术进步：液态切片和基因组分析等检测方法的创新正在推动市场发展。最重要的是，这些创新将提高精准度，针对特定的治疗方法，并改善患者获得多样化治疗方法的机会。

2. 癌症发生率不断上升：全球癌症发生率的不断上升要求更好的检测技术。随着越来越多的人寻求早期诊断服务和适当的治疗方法，固态肿瘤检测市场持续成长。

3. 转向个人化治疗：人们对精准医疗的兴趣日益浓厚，推动着固态肿瘤检测的模式转移。越来越多的患者和医疗保健提供者寻求能够揭示特定突变的测试，以便采用更有效的标靶治疗进行治疗。

4. 政府政策激励：监管机构鼓励创新测试理念并缩短新设备的上市时间。这样的氛围将鼓励研发活动，并最终增加最新和先进诊断设备的供应。

5. 医疗保健资金的成长：固态肿瘤检测市场的成长受到公共和私人机构对医疗保健基础设施和生物技术的投资所推动。资金筹措的增加将鼓励创造和使用复杂的诊断方法。

固态肿瘤检测市场面临的挑战包括：

1. 监管障碍：虽然有时可以获得监管部门的核准，但获得新技术的核准可能具有挑战性。创新公司将难以将尖端解决方案推向市场，从而损害其竞争力。

2. 市场分散：次发性恶性肿瘤检测市场整合度较低，许多相关人员提供不同的服务。这种分散性导致医疗保健提供者和患者感到困惑，从而导致错误的检测选择。

支持固态肿瘤检测市场发展的因素与阻碍其扩张的因素之间的平衡非常明确。为了改善患者照护并促进癌症诊断的有效和进步发展，必须利用现有的技术发展并应对挑战。

目录

第一章执行摘要

2. 全球固态肿瘤检测市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球固态肿瘤检测市场趋势（2019-2024）及预测（2025-2031）
• 全球固态肿瘤检测市场（按类型）
  • 基因检测
  • 常规测试
• 全球固态肿瘤检测市场（按应用）
  • 摄护腺
  • 胸部
  • 冒号
  • 子宫内膜
  • 肺
  • 恶性黑色素瘤
  • 其他的
• 全球固态肿瘤检测市场（依最终用途）
  • 医院
  • 製药和生物技术公司
  • 受託研究机构
  • 学术研究所

第四章。各地区市场趋势及预测分析（2019-2031）

• 固态肿瘤检测市场（按地区）
• 北美固态肿瘤检测市场
• 欧洲固态肿瘤检测市场
• 亚太固态肿瘤检测市场
• 世界其他地区固态肿瘤检测市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球固态肿瘤检测市场成长机会（按类型）
  • 全球固态肿瘤检测市场的成长机会（按应用）
  • 全球固态肿瘤检测市场的成长机会（按最终用途划分）
  • 全球固态肿瘤检测市场各区域成长机会
• 全球固态肿瘤检测市场的新趋势
• 战略分析
  • 新产品开发
  • 全球固态肿瘤检测市场的产能扩张
  • 全球固态肿瘤检测市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业简介

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

The future of the global solid tumor testing market looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1699.2 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.

• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
• In terms of regions, North America is expected to witness the largest growth over the forecast period due to a rise in various organ-specific cancer cases, supported by a robust healthcare infrastructure.

Gain Valuable Insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Solid Tumor Testing Market

The solid tumor testing market is being shaped by emerging trends in the field that are changing the aspects of diagnostics and treatment methods. These trends are marked by differences in technologies, changes in the healthcare system, and a shift in focus toward the patient.

• Liquid Biopsy Technology: Liquid biopsy technology includes the examination of liquid samples from patients to identify solid tumors by analyzing circulating tumor DNA (ctDNA). Monitoring tumor behavior and its changes can help improve the personalization of treatment and decrease the number of invasive procedures used.
• Genomic Profiling: Comprehensive genomic profiling is becoming an essential component of cancer management as it helps in the detection of mutations in different tumors. In this context, agents that promote the creation of drugs that target specific molecules are likely to be beneficial to patients, especially in cases of cancer types with metastatic potential.
• Integration of AI and Machine Learning: The use of AI and machine learning in performing solid tumor tests improves the accuracy and speed of diagnosis. Such technologies analyze vast amounts of data to identify potential trends and forecast the outcomes of treatments, assisting doctors in formulating appropriate treatment measures.
• Increased Focus on Early Detection: There is an increasing focus on the early detection of solid tumors, as this significantly increases the chances of successfully treating affected individuals. There is a need to develop strategies for providing regular check-ups and advanced diagnostic approaches to ensure that cancers are detected at an earlier stage when they are most treatable.
• Regulatory Attitude Towards Technology: Regulatory authorities have started to recognize and promote more innovative and novel diagnostic solutions, which accelerate the approval of new technologies and streamline the approval systems. This scenario is supportive of both the establishment and practice of research and development, which will, in turn, increase the chances of these sophisticated testing procedures becoming commonplace in routine use.

These new trends are revitalizing the solid tumor testing segment of the market by strengthening the capabilities of diagnostics, encouraging targeted approaches, and improving the healthcare provided. With the rapid rate of technological changes, it will not be surprising to find that all these trends will be integrated in further tackling the problems associated with cancer.

Recent Developments in the Solid Tumor Testing Market

The market for solid tumor testing has its share of developments that stand out with improvements in the accuracy and management of treatment. Such trends are all towards an increase in personalized medicine and a demand for advancements in treatment technology concerning cancer.

• Liquid Biopsy Advancements: Recent developments in the liquid biopsy field have allowed for the non-invasive detection of solid tumors via the analysis of ctDNA bioassays. This development significantly augments the surveillance of patients and any changes that may be made in the course of treatment, showing how the tumor is behaving as well as the effects of the treatment given.
• Genomic Profiling Approvals: The endorsement of policies for the approval of diverse molecular profiling tests by health regulators has made access to selected therapies easier. Using these tests, oncologists can isolate certain mutations that, in turn, lead to tailored surgical intervention plans that improve positive outcomes and reduce negative effects in patients.
• AI-Driven Diagnostics: The use of artificial intelligence systems in testing solid tumors is changing the way things are done in the industry. AI techniques are better equipped to evaluate multifaceted data compared to traditional approaches, thereby making diagnosis and treatment processes faster by providing more informed treatment options for patients.
• Collaborative Research Initiatives: Collaboration between universities and biotech firms has fostered the improvement of cancer diagnostic techniques. International collaboration, for example, supports technology development and improves testing strategies so that advanced technologies reach clinicians more quickly.
• Global Standardization Efforts: The global standardization movement of solid tumor biological diagnostic testing procedures is gaining the momentum it deserves. It seeks the harmonization of diagnostic testing strategies so that uniformity and reproducibility of particular tests are achieved, which will, in turn, improve the quality of care for patients worldwide.

These key advancements have benefited the solid tumor testing market through better diagnosis, extended treatment alternatives, and effective patient management. It is clear that emphasizing the challenges and possible solutions brings about more opportunities for future developments in this field.

Strategic Growth Opportunities for Solid Tumor Testing Market

The geometrical progression that attracts attention in the area of solid tumor testing encompasses diverse strategic exclusion options related to the component geosystems basis territory diversified. The development of specific potential values helps address the challenges that enhance the diagnosis processes and treatment outcomes.

• Introduction of Personalized Medicine: Personalized medicine has made it possible to design unique tests that are appropriate for an individual patient. A comprehensive investigation of genes can help devise new strategies that are more effective in treating diseases and improving the health status of patients.
• Advancing the Liquid Biopsy Market: Looking at the growing trend of non-invasive testing, companies have an opportunity to enhance their liquid biopsy systems and services. This trend helps not only to make patients comfortable but also allows better measurement of treatment response.
• Using AI Technology for Diagnostics: The application of AI in solid tumor testing creates new pathways for the development of intelligent diagnostic solutions. These can sift through a massive amount of information systematically to improve the accuracy of tests, increase workflow efficiency, and reduce the time taken to arrive at a diagnosis.
• There is a growing need for early detection: Increased understanding of cancer and its early symptoms has necessitated the need for better screening tools. Thus, companies that invest in bringing forth better early detection tests for the market can gain more from this growing need in the industry, which, in turn, leads to a larger market share from the expanding clientele.
• Developed Markets Target-Expansion of Overseas Operations: Emerging markets, especially in Asia and Africa, will prove to be great avenues for the solid tumor testing business. Companies that can strategically enter these areas will find an increasing number of patients seeking better ways to diagnose their diseases.

These forward-looking growth strategies are redefining the solid tumor testing market by focusing on precision medicine, technology, and novel diagnostic solutions. Providers who pursue these opportunities will capture more market share and enhance the quality of care provided to patients.

Solid Tumor Testing Market Driver and Challenges

Similar to solid tumor testing within the market, the upcoming solid tumor testing market also suffers from several technological, economic, and regulatory factors that act as both enablers and inhibitors. Understanding these dynamics is important for stakeholders as the environment continues to change.

The factors responsible for driving the solid tumor testing market include:

1. Technological Advancements: Technological innovations in testing methods, including liquid biopsies and genomic profiling, are fueling the market. Most importantly, these innovations increase accuracy, target specific therapies, and improve patient access to diverse treatments.

2. Increasing Cancer Incidence: The increasing global burden of cancer is demanding better testing techniques. As more people request early diagnosis services and suitable therapies, the market for solid tumor testing continues to grow.

3. Shift Towards Individualized Treatment: There is a paradigm shift in solid tumor testing driven by an increasing focus on precision medicine. More and more, patients and providers are looking for tests that can reveal particular mutations that can then be treated with more effective targeted therapies.

4. Government Policy Encouragement: Regulatory authorities are promoting innovative testing ideas and shortening the duration of introducing new devices to the market. This atmosphere favors conducting R&D activities, which ultimately results in an increased supply of modern and advanced diagnostic equipment.

5. Growth in Healthcare Financing: Growth in the solid tumor testing market is fueled by investment in healthcare infrastructure and biotechnology by public and private institutions. Improved funding facilitates the creation and use of sophisticated diagnostic approaches.

Challenges in the solid tumor testing market include:

1. Regulatory Hurdles: Although regulatory endorsement is acquired in some cases, it is not straightforward to gain approval for new technology. Innovative companies experience problems launching their cutting-edge solutions, which negatively impacts competition.

2. Market Fragmentation: The market for testing malignant secondary tumors is poorly consolidated, and many stakeholders offer different services. This fragmentation leads to confusion among medical practitioners and patients, resulting in poor choices regarding testing.

The balance of factors that support the development and barriers to the expansion of the solid tumor testing market is quite evident. It is essential to utilize available technological developments and address challenges to improve patient care and foster the effective and progressive development of cancer diagnostics.

List of Solid Tumor Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies solid tumor testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include-

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

Solid Tumor Testing by Segment

The study includes a forecast for the global solid tumor testing market by type, application, end use, and region.

Solid Tumor Testing Market by Type [Analysis by Value from 2019 to 2031]:

• Genetic Testing
• Conventional Testing

Solid Tumor Testing Market by Application [Analysis by Value from 2019 to 2031]:

• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others

Solid Tumor Testing Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions

Solid Tumor Testing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Solid Tumor Testing Market

The solid tumor testing market is undergoing dramatic changes in some countries primarily due to technological breakthroughs and increases in healthcare expenditure and focus on personalized medicine. This is particularly true for the United States, China, Germany, India, and Japan, each of which is progressing in specific areas to enhance diagnostic devices and therapeutic approaches.

• USA: There is rapid development of liquid biopsy technologies, which revolutionize the way cancer is diagnosed through non-invasive methods for solid tumors that do not require invasive surgery. With the increasing number of approvals for genomic profiling tests, it is possible to develop targeted therapies. Apart from this, partnerships between biotech companies and healthcare providers enhance diagnostics.
• China: Such development in China regarding the solid tumor market is observed primarily because of the influx of public funds in the field of biotechnology, including healthcare. An increase in inhibitory activity in management, including management of precision medicine programs, is witnessed with a growing volume in the utilization of complicated genomic tests. No affordable management has grown this change for focal management specifically at centers, as they reduce the rate of delay and assist in developing better management strategies.
• Germany: Germany's solid tumor testing market is supported by impressive research activity and collaboration between research institutes and businesses. The country is moving toward next-generation sequencing (NGS) technologies, which further improve diagnostic accuracy and support the implementation of specific treatments. Innovative testing approaches are also being accepted, as improvements in regulatory guidance encourage the development of new diagnostic methods.
• India: The solid tumor testing market is fueled by the growing incidence of cancer among the population in India. Low-cost genomic diagnostic tests, developed for the majority of the population by emerging companies, promote early diagnosis and treatment personalization. Improvements in cancer diagnostics are also aided by increased public awareness and government policies.
• Japan: Japan is expanding its solid tumor testing market by employing new imaging methodologies along with NGS in the field of solid tumors. The government is encouraging doctors to adopt precision medicine concepts, resulting in more mechanisms for treating cancers. Marketing drafts created in cooperation with Japanese companies and foreign companies have expanded the supply of new diagnostic methods.

Features of the Global Solid Tumor Testing Market

Market Size Estimates: Solid tumor testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Solid tumor testing market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Solid tumor testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the solid tumor testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Solid Tumor Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Solid Tumor Testing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Solid Tumor Testing Market by Type
  • 3.3.1: Genetic Testing
  • 3.3.2: Conventional Testing
• 3.4: Global Solid Tumor Testing Market by Application
  • 3.4.1: Prostate
  • 3.4.2: Breast
  • 3.4.3: Colorectal
  • 3.4.4: Endometrial
  • 3.4.5: Lung
  • 3.4.6: Melanoma
  • 3.4.7: Others
• 3.5: Global Solid Tumor Testing Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Pharmaceutical & Biotechnology Companies
  • 3.5.3: Contract Research Organizations
  • 3.5.4: Academic Research Institutions

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Solid Tumor Testing Market by Region
• 4.2: North American Solid Tumor Testing Market
  • 4.2.1: North American Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.2.2: North American Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.3: European Solid Tumor Testing Market
  • 4.3.1: European Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.3.2: European Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.4: APAC Solid Tumor Testing Market
  • 4.4.1: APAC Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.4.2: APAC Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.5: ROW Solid Tumor Testing Market
  • 4.5.1: ROW Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.5.2: ROW Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Solid Tumor Testing Market by Type
  • 6.1.2: Growth Opportunities for the Global Solid Tumor Testing Market by Application
  • 6.1.3: Growth Opportunities for the Global Solid Tumor Testing Market by End Use
  • 6.1.4: Growth Opportunities for the Global Solid Tumor Testing Market by Region
• 6.2: Emerging Trends in the Global Solid Tumor Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Solid Tumor Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Solid Tumor Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Agilent Technologies
• 7.2: MYRIAD GENETICS
• 7.3: Biocare Medical
• 7.4: ILLUMINA
• 7.5: F. Hoffmann-La Roche
• 7.6: QIAGEN
• 7.7: MedGenome Labs
• 7.8: Thermo Fisher Scientific
• 7.9: Abbott Laboratories
• 7.10: QUEST DIAGNOSTICS